STOCK TITAN

Iovance Biotherp - IOVA STOCK NEWS

Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.

Iovance Biotherapeutics (IOVA) pioneers tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers, leading the next generation of personalized immunotherapies. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.

Access timely announcements including FDA submissions, clinical trial data publications, manufacturing advancements, and partnership agreements. Our curated collection ensures you stay informed about IOVA developments impacting oncology treatment paradigms and biopharmaceutical innovation.

Key updates cover therapy approvals, research collaborations, financial results, and scientific presentations. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Iovance's latest progress in developing TIL-based therapies for melanoma, cervical cancer, and other solid tumors. Regularly updated to serve as your definitive resource for IOVA-related news analysis.

Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) granted 44,175 inducement stock options to four new non-executive employees. Each option has an exercise price of $7.89 and vests over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced the approval of inducement stock options for new non-executive employees. The options cover 59,950 shares, with an exercise price of $4.40 and vesting over a three-year period. The awards were granted under Iovance’s 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.71%
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reports FDA Priority Review of Biologics License Application (BLA) for lifileucel in advanced melanoma on track for PDUFA date of February 24, 2023. Positive regulatory feedback supports lifileucel regulatory submissions in Europe and Canada in 2024. Onboarding completed at approximately 30 Authorized Treatment Centers (ATCs) in preparation for potential U.S. commercial launch of lifileucel as first approved TIL therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
Rhea-AI Summary
Iovance Biotherapeutics, Inc. will report its Q3 and year-to-date 2023 financial results on November 7, 2023. The company focuses on developing novel polyclonal tumor infiltrating lymphocyte therapies for cancer patients. A conference call and live audio webcast will be held at 4:30 p.m. ET to discuss the results and provide a corporate update. The webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
conferences earnings
-
Rhea-AI Summary
Iovance Biotherapeutics announced the publication of abstracts for poster presentations at the SITC Annual Meeting. The four-year analysis of the C-144-01 trial showed lifileucel TIL therapy demonstrated durable efficacy with a four-year overall survival rate of 22.2%. The longest response was ongoing at 59.9 months. Treatment-emergent adverse events were consistent with known safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
conferences clinical trial
-
Rhea-AI Summary
Iovance Biotherapeutics grants inducement stock options to new non-executive employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
none
Rhea-AI Summary
Iovance Biotherapeutics presents clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at SITC Annual Meeting. Long-term efficacy and safety of lifileucel TIL cell therapy in patients with advanced melanoma reported. TIL with IL-12 show superior antitumor activity. Phase 3 study of lifileucel TIL therapy combined with pembrolizumab in progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences clinical trial
-
Rhea-AI Summary
Iovance Biotherapeutics grants inducement stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.16%
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics extends PDUFA date for lifileucel to Feb 24, 2024 due to FDA resource constraints. FDA agrees to expedite remaining review. No major issues found. All facility inspections completed. No advisory committee meeting planned. Positive data supports accelerated approval. TILVANCE-301 trial on track.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.58%
Tags
none
Rhea-AI Summary
Iovance Biotherapeutics to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
conferences
Iovance Biotherp

Nasdaq:IOVA

IOVA Rankings

IOVA Stock Data

1.00B
279.26M
0.62%
84.02%
18.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN CARLOS